{"id":56322,"date":"2026-05-20T19:56:00","date_gmt":"2026-05-20T12:56:00","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=56322"},"modified":"2026-05-20T19:56:00","modified_gmt":"2026-05-20T12:56:00","slug":"pictor-and-disease-research-limited-formalise-collaboration-to-advance-johnes-disease-monitoring-across-new-zealand","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=56322","title":{"rendered":"Pictor and Disease Research Limited Formalise Collaboration to Advance Johne’s Disease Monitoring Across New Zealand"},"content":{"rendered":"\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Building on a two-year scientific collaboration and co-authored peer-reviewed publication, the collaboration supports<\/i>\u00a0new approaches<\/i>\u00a0to herd health monitoring for New Zealand’s dairy and beef sectors<\/i><\/p>\n

AUCKLAND, New Zealand<\/span>, May 20, 2026<\/span> \/PRNewswire\/ — Pictor, a global targeted proteomics platform company founded in New Zealand, today announced it has\u00a0formalised\u00a0a collaboration with Disease Research Limited (DRL), a leading New Zealand veterinary diagnostic laboratory based at Invermay Research Centre in Mosgiel, Dunedin. The collaboration\u00a0formalises\u00a0an existing scientific relationship and\u00a0establishes\u00a0a joint framework for the validation and launch planning of\u00a0PictVet\u00ae<\/sup> Mycobacterium avium<\/i> subspecies paratuberculosis <\/i>(MAP) IgG Multiplex ELISA Kit\u00a0\u2014 the bacterium associated with Johne’s disease in cattle.<\/p>\n

Johne’s disease\u00a0remains\u00a0a significant challenge for New Zealand’s dairy and beef industries. MAP infection is estimated to be present in a\u00a0substantial\u00a0portion\u00a0of New Zealand dairy herds, contributing meaningful economic impact across the sector.1<\/sup> Despite its prevalence, participation in routine whole-herd monitoring remains variable, with uptake influenced by the operational and practical challenges associated with existing single-analyte approaches.<\/b><\/p>\n

Pictor’s\u00a0PictVet\u00ae<\/sup>\u00a0MAP assay uses a multi-analyte targeted proteomic approach that incorporates several MAP-specific antigens to broaden antibody analysis in subclinical cases.\u00a0The assay is designed for use with both milk and<\/b>\u00a0serum<\/b>\u00a0samples, offering flexibility to support a range of herd-level testing workflows for farming operations.<\/b><\/p>\n

The collaboration builds on a relationship\u00a0established\u00a0in 2024 under a Product Development Framework Agreement between the two\u00a0organisations. DRL’s Simon Liggett, Director and Laboratory Manager, was a co-author on a peer-reviewed publication in\u00a0Frontiers in Veterinary Science<\/i>\u00a0in 2025 that reported preliminary validation data related to the\u00a0PictVet\u00ae<\/sup>\u00a0MAP assay.2<\/sup>\u00a0Further studies are currently underway in New Zealand with involvement from DRL and additional industry collaborators.<\/p>\n

“New Zealand’s livestock industry has long been a global leader in animal health innovation, making DRL an ideal collaborator for this work. By combining DRL’s<\/i>\u00a0expertise<\/i>\u00a0in veterinary laboratory workflows with Pictor’s targeted proteomic assay platform, we aim to support more practical and scalable herd health monitoring approaches for farmers and veterinarians across New Zealand.”<\/i>
\u2014 Jamie Platt, PhD, CEO and Co-founder, Pictor<\/b>\u00a0<\/p>\n

“DRL and Pictor share common values in approaching assay development from a multi-analyte perspective. This approach adds value for farmers and veterinarians by supporting broader herd insights and more informed on-farm management decisions. We are excited by the work being done together and look forward to future collaborations.”<\/i>
\u2014 Sara Ferguson, Director and Operations Manager, Disease Research Limited<\/b>\u00a0<\/p>\n

Both\u00a0organisations\u00a0also plan to engage with stakeholders at the New Zealand Veterinary Association\u00a0(NZVA) Annual Conference in Auckland, June 23\u201325, 2026,\u00a0where progress related to the collaboration will be shared with members of the veterinary community.<\/p>\n

Note to editors: Published validation findings referenced above are preliminary and based on a limited validation cohort. Larger multi-farm studies are currently underway. The<\/i>\u00a0PictVet\u00ae MAP assay is for research use only (RUO) and is not intended for clinical or veterinary decision-making.<\/i>\u00a0<\/p>\n

About Pictor
<\/b>Pictor is a global targeted\u00a0proteomic\u00a0platform\u00a0company\u00a0founded in New Zealand and headquartered in Carlsbad, California, with operations in New Zealand, Australia, and India. The company develops multi-analyte proteomic assay solutions for human and animal health, combining broad sample compatibility and AI-assisted analysis to deliver actionable laboratory insights for research and testing environments worldwide. Pictor’s animal health platform,\u00a0PictVet\u00ae<\/sup>, is designed to support livestock health monitoring across multiple disease states. For more information, www.pictorproteomics.com<\/a>.<\/p>\n

About Disease Research Limited (DRL)
<\/b>Disease Research Limited is a specialist New Zealand veterinary diagnostic laboratory based at Invermay Research Centre in Mosgiel, Dunedin. DRL provides laboratory services and applied research support to New Zealand’s livestock industries, with a focus on herd health monitoring, livestock testing workflows, and collaborative industry research initiatives. For more information, visit www.drl.net.nz<\/a>.<\/p>\n

Media Contact
<\/b>Kelly Krueger
<\/b>Audacity Health\u00a0on behalf of Pictor
415-235-5031
Kelly.krueger@audacityhealth.com<\/a>
www.pictordx.com<\/a>\u00a0<\/p>\n

References<\/b><\/p>\n

1<\/sup>\u00a0 Johne’s\u00a0Information Centre New Zealand. Economic impact of Johne’s disease in New Zealand dairy herds. Accessed May 2026.
2<\/sup>\u00a0 Chiu\u00a0SJ,\u00a0Bugde\u00a0P, Kinga A, et al. Multiplex biomarker-based ELISA enables early detection of Mycobacterium avium<\/i> subspecies paratuberculosis<\/i>-specific antibodies comparable to IFN-\u03b3 testing.\u00a0Front Vet Sci.<\/i> 2025. doi:10.3389\/fvets.2025.1749510<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n\n\n\n
\"\"<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Building on a two-year scientific collaboration and co-authored peer-reviewed publication, the collaboration supports<\/i>\u00a0new approaches<\/i>\u00a0to herd health monitoring for New Zealand’s dairy and beef sectors<\/i><\/p>\n

AUCKLAND, New Zealand<\/span>, May 20, 2026<\/span> \/PRNewswire\/ — Pictor, a global targeted proteomics platform company founded in New Zealand, today announced it has\u00a0formalised\u00a0a collaboration with Disease Research Limited (DRL), a leading New Zealand veterinary diagnostic laboratory based at Invermay Research Centre in Mosgiel, Dunedin. The collaboration\u00a0formalises\u00a0an existing scientific relationship and\u00a0establishes\u00a0a joint framework for the validation and launch planning of\u00a0PictVet\u00ae<\/sup> Mycobacterium avium<\/i> subspecies paratuberculosis <\/i>(MAP) IgG Multiplex ELISA Kit\u00a0\u2014 the bacterium associated with Johne’s disease in cattle.<\/p>\n

Johne’s disease\u00a0remains\u00a0a significant challenge for New Zealand’s dairy and beef industries. MAP infection is estimated to be present in a\u00a0substantial\u00a0portion\u00a0of New Zealand dairy herds, contributing meaningful economic impact across the sector.1<\/sup> Despite its prevalence, participation in routine whole-herd monitoring remains variable, with uptake influenced by the operational and practical challenges associated with existing single-analyte approaches.<\/b><\/p>\n

Pictor’s\u00a0PictVet\u00ae<\/sup>\u00a0MAP assay uses a multi-analyte targeted proteomic approach that incorporates several MAP-specific antigens to broaden antibody analysis in subclinical cases.\u00a0The assay is designed for use with both milk and<\/b>\u00a0serum<\/b>\u00a0samples, offering flexibility to support a range of herd-level testing workflows for farming operations.<\/b><\/p>\n

The collaboration builds on a relationship\u00a0established\u00a0in 2024 under a Product Development Framework Agreement between the two\u00a0organisations. DRL’s Simon Liggett, Director and Laboratory Manager, was a co-author on a peer-reviewed publication in\u00a0Frontiers in Veterinary Science<\/i>\u00a0in 2025 that reported preliminary validation data related to the\u00a0PictVet\u00ae<\/sup>\u00a0MAP assay.2<\/sup>\u00a0Further studies are currently underway in New Zealand with involvement from DRL and additional industry collaborators.<\/p>\n

“New Zealand’s livestock industry has long been a global leader in animal health innovation, making DRL an ideal collaborator for this work. By combining DRL’s<\/i>\u00a0expertise<\/i>\u00a0in veterinary laboratory workflows with Pictor’s targeted proteomic assay platform, we aim to support more practical and scalable herd health monitoring approaches for farmers and veterinarians across New Zealand.”<\/i>
\u2014 Jamie Platt, PhD, CEO and Co-founder, Pictor<\/b>\u00a0<\/p>\n

“DRL and Pictor share common values in approaching assay development from a multi-analyte perspective. This approach adds value for farmers and veterinarians by supporting broader herd insights and more informed on-farm management decisions. We are excited by the work being done together and look forward to future collaborations.”<\/i>
\u2014 Sara Ferguson, Director and Operations Manager, Disease Research Limited<\/b>\u00a0<\/p>\n

Both\u00a0organisations\u00a0also plan to engage with stakeholders at the New Zealand Veterinary Association\u00a0(NZVA) Annual Conference in Auckland, June 23\u201325, 2026,\u00a0where progress related to the collaboration will be shared with members of the veterinary community.<\/p>\n

Note to editors: Published validation findings referenced above are preliminary and based on a limited validation cohort. Larger multi-farm studies are currently underway. The<\/i>\u00a0PictVet\u00ae MAP assay is for research use only (RUO) and is not intended for clinical or veterinary decision-making.<\/i>\u00a0<\/p>\n

About Pictor
<\/b>Pictor is a global targeted\u00a0proteomic\u00a0platform\u00a0company\u00a0founded in New Zealand and headquartered in Carlsbad, California, with operations in New Zealand, Australia, and India. The company develops multi-analyte proteomic assay solutions for human and animal health, combining broad sample compatibility and AI-assisted analysis to deliver actionable laboratory insights for research and testing environments worldwide. Pictor’s animal health platform,\u00a0PictVet\u00ae<\/sup>, is designed to support livestock health monitoring across multiple disease states. For more information, www.pictorproteomics.com<\/a>.<\/p>\n

About Disease Research Limited (DRL)
<\/b>Disease Research Limited is a specialist New Zealand veterinary diagnostic laboratory based at Invermay Research Centre in Mosgiel, Dunedin. DRL provides laboratory services and applied research support to New Zealand’s livestock industries, with a focus on herd health monitoring, livestock testing workflows, and collaborative industry research initiatives. For more information, visit www.drl.net.nz<\/a>.<\/p>\n

Media Contact
<\/b>Kelly Krueger
<\/b>Audacity Health\u00a0on behalf of Pictor
415-235-5031
Kelly.krueger@audacityhealth.com<\/a>
www.pictordx.com<\/a>\u00a0<\/p>\n

References<\/b><\/p>\n

1<\/sup>\u00a0 Johne’s\u00a0Information Centre New Zealand. Economic impact of Johne’s disease in New Zealand dairy herds. Accessed May 2026.
2<\/sup>\u00a0 Chiu\u00a0SJ,\u00a0Bugde\u00a0P, Kinga A, et al. Multiplex biomarker-based ELISA enables early detection of Mycobacterium avium<\/i> subspecies paratuberculosis<\/i>-specific antibodies comparable to IFN-\u03b3 testing.\u00a0Front Vet Sci.<\/i> 2025. doi:10.3389\/fvets.2025.1749510<\/p>\n

<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-56322","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/56322","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56322"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/56322\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56322"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56322"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56322"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}